Design, Synthesis and Characterization of Mn(II)Cysteine-Tyrosine Dithiocarbamate Complex for against the Cancer on MCF-7 Breast Cancer Cell Line

Abstract

Objective: Breast cancer is the most frequently diagnosed cancer and the second cause of death worldwide. The drug often used for chemotherapy is cisplatin. However, the drug cisplatin has a number of problems, including lack of selectivity, undesirable side effects, resistance, and toxicity in the body. So research is carried out on new drug compounds with low toxicity by designing in silico with molecular docking.

Methods: Mn(II) Cysteine-Tyrosine dithiocarbamate is a new complex molecule whose research involves several steps, such as in-silico molecular docking testing with target proteins, ADMET then synthesis, characterization and in-vitro MCF-7 cells for anticancer drugs. The synthesis process involves the reaction of manganese metal with tyrosine, cysteine, CS2 and KOH. Characterization tests have been carried out including FT-IR spectroscopy, SEM-EDS, UV Vis, conductivity, melting point and XRD.

Result: Confirm the structure of the compound using UV Vis, obtained orbitals π to π* and n to π* in the group N = C = S is represented by the absorption at 400 nm and 600 nm, FT-IR with the results obtained by the functional groups O-H, N-H, C =N and C=S. In vitro test results showed morphological changes (apoptosis) in MCF-7 cancer cells starting from 250 μg/mL and an IC50 value of 416.90 µg/mL. Molecular docking studies of the Mn(II)Cysteine-Tyrosine dithiocarbamate complex were identified with 4,4',4''-[(2R)-butane-1,1,2-triyl]triphenol - Estrogen α which showed an active site with amino acid residues GLU323, GLU385, VAL446, ILE514, TRP360, LYS449, MET388, MET357, PHE445, VAL392 and ILE389. Hydrophobic and hydrophobic bonds are seen in Mn(II)Cysteine-Tyrosine dithiocarbamate - Estrogen α has a bond energy of -77.5372 kJ/mol.

Conclusion: Despite having a high H-bond interaction intensity, the chemical does not have a powerful enough anticancer impact. Despite the produced compound's low bioactivity, this study should offer important new understandings into how molecular structure affects anticancer activity.

Keywords: Complex; IC50; MCF-7 cell lines; Mn(II)Cysteine-Tyrosine dithiocarbamate; Molecular docking.

Figure 1

Docking Visualization of 4,4',4''-[(2R)-butane-1,1,2-triyl]triphenol (control +) against Estrogen Receptor α

Figure 2

Docking Visualization of Mn(II)cysteine-tyrosine-dithiocarbamate against Estrogen Receptor α

Figure 3

Synthesis Reaction of Mn(II)cysteine-tyrosineditiocarbamate Complex Compound

Figure 4

UV-Vis Spectrum of Mn(II)cysteine-tyrosine Ditiocarbamate Complex

Figure 5

IR Spectrum of Mn(II)cysteine-tyrosine Ditiocarbamate Complex

Figure 6

XRD Spectrum of Mn(II)cysteine-tyrosine Ditiocarbamate Complex

Figure 7

Morphology and SEM-EDS of Mn(II)cysteine-tyrosine Ditiocarbamate Complex

Figure 8

Well Plate Documentation of Mn(II)cysteine-tyrosine Ditiocarbamate Results on MCF-7 Cells

Figure 9

MCF-7 Cell Apoptosis Induced by Mn(II)cysteine-tyrosine Dithiocarbamate